Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: Ahmad Gharabli/AFP via Getty Images

Benny Gantz, the leader of Israel's Blue and White party and the main political opponent to Israeli Prime Minister Benjamin Netanyahu, is considering turning down President Trump’s invitation to come to Washington next week to discuss the U.S. Israeli-Palestinian peace plan.

The big picture: Blue and White officials tell me Gantz and his aides are concerned the invitation to Washington is a political trap orchestrated by Netanyahu a little more than a month before the country's elections on March 2.

  • Gantz met this morning with his party leadership to discuss whether he should reject Trump’s invitation.
  • The officials added that there was great concern in the meeting that going to Washington could do more harm than good and leave Gantz humiliated politically.

The state of play: Gantz was upset by the Vice President Pence's statement Thursday that said the White House was acting according to Netanyahu's recommendations when it invited him to Washington, according to the officials.

  • Gantz and his aides were also unhappy with the White House statement which said Trump invited Netanyahu "to the White House" while merely inviting Gantz "to Washington."
  • That's led to fears among Blue and White officials that Netanyahu would get a meeting with Trump —and a big ceremony around the peace plan — while Gantz would get a lower-level meeting that would make him look "like a second fiddle."

Why it matters: Gantz is stuck between a rock and a hard place with his decision.

  • Accepting the invitation and coming to Washington when the main talks will be between Trump and Netanyahu could portray him as a fifth wheel — or worse, a cheerleader for Netanyahu’s foreign policy.
  • Rejecting the invitation could insult Trump, inciting retaliation from the president, and portray Gantz as a politician who can’t handle the relationship with Israel's most important ally.

What he's saying: Gantz spoke today with U.S. Ambassador to Israel David Friedman and told him that — although he generally supports the peace plan and will welcome it publicly once it is presented — he thinks the going to Washington on an uneven basis with Netanyahu could harm him in the elections.

  • According to sources briefed on the call, Friedman told Gantz that there was no political motivation behind the White House actions and that he will most likely will get a meeting with Trump.

What's next: Blue and White officials said they want to hear more details from the White House about the plan for the visit before they make a final decision.

  • Gantz is expected to give a statement Saturday to announce both his decision and his position on Trump's peace plan.

Go deeper: Gantz changes course, calls on Trump to release Middle East peace plan

Go deeper

Felix Salmon, author of Capital
6 mins ago - Economy & Business

How the pandemic caused a corporate rebound

Illustration: Sarah Grillo/Axios

WeWork becomes a public company today worth more than $9 billion — a vindication of the expensive turnaround strategy employed after it spectacularly imploded in 2019. Like many companies that find themselves at death's door, that which didn't kill them made them stronger.

Why it matters: Hertz, Alamo Drafthouse, Airbnb, and Toast are among the currently-thriving companies that were shaken to the core in the early days of the pandemic — providing further evidence for the theory that, in the words of former Fast Company editor Bill Taylor, "companies can't be great unless they've almost failed."

36 mins ago - Health

Aduhelm is bombing

The average list price of Aduhelm is roughly $4,300 per monthly infusion. Photo: Biogen

Biogen sold $300,000 worth of Aduhelm in the third quarter, well below Wall Street's expectations, which prompted analysts at Raymond James to call the Alzheimer's drug "potentially the worst drug launch of all time" amid Biogen's "persistent hyperbole about the drug's purported benefits."

The big picture: Aduhelm's controversial approval and high price tag have shaped the market reaction. Health insurers are hesitant to cover Aduhelm until Medicare makes a decision next year, and doctors aren't embracing the drug either.

36 mins ago - Health

COVID cases and deaths keep falling

Expand chart
Data: N.Y. Times; Cartogram: Kavya Beheraj/Axios

America’s coronavirus outbreak is rapidly improving as the Delta wave recedes, and vaccines for kids — which could become available within weeks — will help the situation improve even further.

By the numbers: Nationwide, the U.S. is now averaging about 79,000 new cases per day — a 22% drop over the past two weeks.